

Therapeutic Divide in New Testosterone Guideline

BY MARY ELLEN SCHNEIDER
New York Bureau

BOSTON — Testosterone therapy should not be offered to all older men with low testosterone levels, according to experts commissioned by the Endocrine Society to examine the treatment of androgen deficiency in adult men.

Guidelines issued by the task force members advise that physicians instead offer testosterone therapy on an individual basis to older men with consistently low testosterone levels on more than one occasion and clinically significant symptoms of androgen deficiency. The guidelines were published in June (*J. Clin. Endocrinol. Metab.* 2006;91:1995-2010).

But task force members disagreed about the serum testosterone threshold that should trigger therapy in older men with symptoms of androgen deficiency, Dr. Shalender Bhasin, chair of the task force, said at the annual meeting of the Endocrine Society. Some would initiate treatment in symptomatic older men with testosterone levels less than 300 ng/dL; others favored a threshold of 200 ng/dL and said the severity of symptoms should guide treatment.

Some would initiate treatment in symptomatic men at less than 300 ng/dL. Others favored a threshold of 200 ng/dL and said symptoms should guide treatment.

The Endocrine Society decided to address the treatment of androgen deficiency because it's an area with rapid advances in basic science and product development. In addition, testosterone prescriptions are up; but at the same time, there is considerable misinformation and controversy surrounding the use of testosterone therapy, said Dr. Bhasin, chief of endocrinology at Boston University.

"We tried to do the right thing," he said. "We anguished a great deal because of the realization that ... we know so little."

The new guidelines are based on systematic reviews of available evidence and discussions among the task force members. The guidelines outline recommendations for diagnosis, screening, treatment, and monitoring for testosterone therapy in adult men with androgen deficiency syndromes.

Diagnosis

The members of the task force opposed screening for androgen deficiency in the general population because of a lack of consensus on the case definition and a lack of data on the public health impact of androgen deficiency.

The experts recommended making the diagnosis of androgen deficiency only in individuals with consistent symptoms and signs of low serum testosterone levels. A diagnosis should not be made during an acute or subacute illness, Dr. Bhasin said.

The diagnosis can be challenging because the signs and symptoms of androgen deficiency are nonspecific and appropriate threshold testosterone levels are

unknown and may depend on age, Dr. Bhasin said. Further, testosterone measures may vary because of circadian rhythms as well as accuracy problems with commercial assays, he said.

The task force advised using a reliable assay to measure the morning total testosterone level to establish the diagnosis and confirming it either by repeating the measurement of morning total testosterone or by measuring the free or bioavailable testosterone level.

Treatment

Testosterone therapy is appropriate in symptomatic men who have classic androgen deficiency syndromes and low testosterone levels, according to the guidelines. The therapy should be used to induce and maintain secondary sex characteristics. It can also be used to improve sexual function, sense of well-being, muscle mass, strength, and bone mineral density.

Testosterone therapy is not appropriate in patients who have metastatic prostate

cancer, breast cancer, or a palpable prostate nodule or induration. Patients with a prostate-specific antigen (PSA) greater than 3 ng/mL without further urologic evaluation are not candidates for testosterone therapy. Other contraindications noted in the guidelines include erythrocytosis, hyperviscosity, untreated obstructive sleep apnea, severe benign prostatic hyperplasia symptoms, or uncontrolled severe heart failure.


Because of a lack of randomized con-

ADVERTISEMENT

INTRA-ABDOMINAL ADIPOSITY (IAA)* ... A MAJOR CARDIOMETABOLIC RISK FACTOR

Adipose tissue is an active endocrine organ, secreting proteins with local and systemic effects.

*As measured by increased waist circumference.



trolled trial data, the task force did not make a recommendation on treating men with prostate cancer who have been disease free for 2 years or more.

For HIV-infected men who have low testosterone levels and weight loss, the task force members suggested short-term testosterone therapy as an adjunctive approach to promote weight maintenance and improvements in lean body mass and muscle strength.

Monitoring

The task force recommended a standardized monitoring plan with evaluation and measures of testosterone levels

at 3 months after initiating treatment and annual assessments.

Hematocrit should be measured at baseline, 3 months, and annually, the task force recommended. If hematocrit exceeds 54%, therapy should be stopped until hematocrit decreases to a safe level. Therapy can be restarted at a lower dose, but evaluations for hypoxia and sleep apnea should be conducted.

The task force recommended urologic consultation if there is a verified serum or plasma PSA concentration of more than 4.0 ng/mL or an increase in serum or PSA concentration of more than 1.4 ng/mL in any 12-month period. ■

Low Testosterone May Up All-Cause Mortality Risk

BY MARY ANN MOON
Contributing Writer

Men with low testosterone levels appear to be at increased risk of death from all causes and to have shorter survival times than men with normal testosterone levels, reported Dr. Molly M. Shores of the departments of psychiatry and behavioral sciences at the

University of Washington, Seattle, and her associates.

In a recent small study, the researchers had unexpectedly found that men with a low testosterone level had higher 6-month mortality than did those with a normal level who were of similar age and had comparable medical morbidity. "Given these unforeseen preliminary findings, we conducted the present retrospective cohort study to examine if repeatedly low serum testosterone levels were associated with increased mortality in a larger sample of middle-aged and elderly men with a longer follow-up, of up to 8 years," they said.

Dr. Shores and her associates identified in a clinical database 858 male veterans, aged 40 years and older, who had undergone at least two measures of testosterone levels between 1994 and 1999 and had then been followed for a mean of 4.3 years. They matched the data on these subjects with data in a national Veterans Affairs death registry to obtain mortality information.

The reasons why these men had undergone testosterone testing were not available for analysis, but previous research has shown that, in general, the most common clinical indications are evaluation of sexual dysfunction, osteoporosis, genitourinary conditions, and endocrine conditions, the investigators said (*Arch. Intern. Med.* 2006;166:1660-5).

A total of 452 men—53% of the study population—had normal serum testosterone levels (defined as 250 ng/dL or higher), or normal free testosterone levels (defined as 0.75 ng/dL or higher). Another 240 men (28%) had equivocal levels, and 166 (19%) had low levels.

Because testosterone levels are known to decrease with both acute and chronic illness, the prevalences of chronic obstructive pulmonary disease, HIV infection, coronary artery disease, and hyperlipidemia were noted. There were no significant differences between the men with normal testosterone levels and those with low testosterone levels regarding these disorders or overall medical morbidity.

All-cause mortality was 20% in men with normal testosterone levels and 25% in those with equivocal levels, compared with 35% in men with low levels. After the data were adjusted to account for the covariates of age, race, body mass index, and other clinical factors, "low testosterone level continued to be associated with an increased mortality risk of 88% greater than in men with normal testosterone levels," Dr. Shores and her associates said.

To control for the confounding influence of possible acute illness, the researchers conducted a further analysis excluding all subjects who died within 1 year of having their testosterone levels measured. In this subset of subjects, low testosterone levels were still associated with a 68% greater mortality risk, compared with normal levels.

The findings do not show that low testosterone levels directly raise mortality risk, because "a retrospective cohort study cannot establish a causal relationship," they cautioned. ■

Brought to you by **sanofi aventis**

INCREASED ACTIVITY OF THE ENDOCANNABINOID SYSTEM (ECS) IS ASSOCIATED WITH INCREASED WAIST CIRCUMFERENCE^{1,2}

INCREASED WAIST CIRCUMFERENCE, A MARKER FOR IAA, IS AN ESTABLISHED CARDIOMETABOLIC RISK FACTOR³

- Significantly increases the risk of myocardial infarction, death from cardiovascular disease, and all-cause mortality⁴
- Has been found to be an independent predictor of type 2 diabetes⁵

ADIPOSE TISSUE IS A HIGHLY ACTIVE ENDOCRINE ORGAN⁶

- Fat cells (adipocytes) produce adiponectin⁶
 - In type 2 diabetes and obesity, adiponectin levels are reduced⁶

TARGETING THE ECS MAY PLAY A POTENTIAL ROLE IN THE CONTROL OF MAJOR CARDIOMETABOLIC RISK FACTORS SUCH AS IAA*

IF YOU ARE INTERESTED IN LEARNING MORE ABOUT THE ECS,
PLEASE CALL 1-800-815-0298 TO RECEIVE A MONOGRAPH.

References

1. DiMarzo V, Matias I. Endocannabinoid control of food intake and energy balance. *Nat Neurosci.* 2005;8:585-589.
2. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *J Clin Invest.* 2003;112:423-431.
3. National Heart, Lung, and Blood Institute. National Cholesterol Education Program. *ATP III Guidelines At-A-Glance: Quick Desk Reference.* Bethesda, Md: National Institutes of Health; May 2001.
4. Dagenais GR, Yi Q, Mann JFE, et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. *Am Heart J.* 2005;149:54-60.
5. Carey VJ, Walters EE, Colditz GA, et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women: the Nurses' Health Study. *Am J Epidemiol.* 1997;145:614-619.
6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab.* 2004;89:2548-2556.